OmniComm Signs TrialOne Contracts in China
April 27th 2017OmniComm Systems recently signed two additional contracts to provide their TrialOne clinical automation solution to two hospitals in China, including the Guangdong General Hospital.OmniComm Systems recently signed two additional contracts to provide their TrialOne clinical automation solution to two hospitals in China, including the Guangdong General Hospital. OmniComm now has a total of five TrialOne agreements in China.Read the full release here
Moffitt Cancer Center Researchers Conduct Pilot Study
April 26th 2017Pensacola, FL - Researchers at the Moffitt Cancer Center in Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in an ongoing cancer quality-of-life study. ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community.
UCB Selects Medidata Clinical Cloud
April 26th 2017Medidata’s Cutting-Edge Technology Platform to Drive Operational Excellence and Patient Value for Global BiopharmaNew York, NY – Medidata, the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that UCB has selected the Medidata Clinical Cloud as its enterprise technology platform.
Coalition for Clinical Trials Awareness Hosts Roundtable
April 25th 2017The Coalition for Clinical Trials Awareness will host a Capitol Hill policy roundtable featuring industry professionals on Wednesday, May 3rd. This event is part of the nationwide Clinical Trials Awareness Week taking place from May 1-5th.Read the full release here
Non-Adherence: A Direct Influence on Clinical Trial Duration and Cost
April 24th 2017As clinical trials remain costly and continue to increase, the promise of novel initiatives gives hope that trial duration and cost impact will drop. However, biopharma continues to overlook one element that affects study timelines: patient non-adherence.
Cliantha Research Acquires Inflamax Research
April 24th 2017Cliantha Research has announced the acquisition of Inflamax Research. Inflamax aims to use its inflammatory disease research and natural allergen Environmental Exposure Chambers (EEC) to assist Cliantha in conducting asthma, allergy, ophthalmology and tobacco research plus specialized pulmonary/respiratory therapeutic studies.Read the full release here